专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO2010056598A3 BIODEGRADABLE ALPHA-2 ADRENERGIC AGONIST POLYMERIC IMPLANTS 审中-公开
公开(公告)号：WO2010056598A3
公开(公告)日：2010-05-20
申请号：PCT/US2009/063490
申请日：2009-11-06
申请人： ALLERGAN, INC. , SPADA, Lon, T. , GHEBREMESKEL, Alazar, N. , ROBINSON, Michael, R.
发明人： SPADA, Lon, T. , GHEBREMESKEL, Alazar, N. , ROBINSON, Michael, R.
IPC分类号： A61K9/00 , A61P27/02 , A61F2/16 , A61K47/34
摘要： Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.

22. 发明申请

WO2007150018A3 STEROID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED METHODS 审中-公开
标题翻译： STEROID含有持续释放内分泌植入物及相关方法
公开(公告)号：WO2007150018A3
公开(公告)日：2008-11-06
申请号：PCT/US2007071871
申请日：2007-06-22
申请人： ALLERGAN INC , WHITCUP SCOTT M , ROBINSON MICHAEL R
发明人： WHITCUP SCOTT M , ROBINSON MICHAEL R
IPC分类号： A61K9/22 , A61K9/00 , A61K31/58
CPC分类号： A61K9/0051 , A61K31/498 , A61K31/573 , A61K31/58 , A61K47/34
摘要： Biocompatible intraocular implant systems are formulated for discontinuous or intermittent release of therapeutic levels of a therapeutic agent (such as a steroid) to minimize development of side effects associated with continuous or long term use of such agent. The implant system may comprise one or more implant, and preferably, although not necessarily, also contains an auxiliary agent having an activity effective to lessen at least one side effect associated with said therapeutic agent compared to the use of an otherwise identical implant system lacking said auxiliary agent. The implants containing the therapeutic agent and auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the ocular side effects otherwise accompanying the use of such therapeutic agent.
摘要翻译：生物相容性眼内植入物系统被配制用于治疗剂量（例如类固醇）的不连续或间歇释放以最小化与这种药剂的连续或长期使用相关的副作用的发展。植入系统可以包括一个或多个植入物，并且优选但不一定也包含具有有效减少与所述治疗剂相关联的至少一种副作用的活性的辅助剂，与使用其它相同的植入物系统相比，缺少所述辅助剂。包含治疗剂和辅助剂的植入物可以放置在眼睛中以治疗一种或多种眼部病症，同时减少否则伴随使用这种治疗剂的眼部副作用。

23. 发明申请

WO2011130462A2 INTRAOCULAR PRESSURE REDUCTION WITH INTRACAMERAL BIMATOPROST IMPLANTS 审中-公开
标题翻译：内镜压力降低内镜压力
公开(公告)号：WO2011130462A2
公开(公告)日：2011-10-20
申请号：PCT/US2011032393
申请日：2011-04-14
申请人： ALLERGAN INC , HUGHES PATRICK M , ROBINSON MICHAEL R , BURKE JAMES A
发明人： HUGHES PATRICK M , ROBINSON MICHAEL R , BURKE JAMES A
IPC分类号： A61K9/70 , A61K31/557 , A61K47/34 , A61P27/02
CPC分类号： A61K9/0051 , A61K9/204 , A61K31/165 , A61K31/557 , A61K31/5575 , A61K47/34
摘要： The present invention provides a method of treating an ocular condition in an eye of a patient, comprising the step of placing a biodegradable intraocular implant in an eye of the patient, the implant comprising a prostamide and a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the prostamide from the implant to provide an amount of the prostamide effective to prevent or reduce a symptom of an ocular condition of the eye, wherein said ocular condition is elevated IOP and said implant is placed in an intracameral location to dilate the outflow channels of the eye emanating from Schlemm's Canal.
摘要翻译：本发明提供了一种治疗患者眼睛中的眼部病症的方法，包括将可生物降解的眼内植入物放置在患者的眼睛中的步骤，所述植入物包含前列腺酰胺和可以以一定速率释放药物的可生物降解的聚合物基质有效地维持从植入物中释放一定量的前列腺酰胺以提供一定量的前列腺酰胺，其有效预防或减少眼睛眼部症状，其中所述眼部病症升高IOP，并且所述植入物置于室内位置，以扩大从施莱姆运河发出的眼睛的流出通道。

24. 发明申请

WO2008070402A2 INTRAOCULAR DRUG DELIVERY SYSTEMS 审中-公开
标题翻译：内分泌药物输送系统
公开(公告)号：WO2008070402A2
公开(公告)日：2008-06-12
申请号：PCT/US2007084224
申请日：2007-11-09
申请人： ALLERGAN INC , ROBINSON MICHAEL R , BLANDA WENDY M , HUGHES PATRICK M , RUIZ GUADALUPE , ORILLA WERHNER C , WHITCUP SCOTT M , LIN JOAN-EN , WELTY DEVIN F
发明人： ROBINSON MICHAEL R , BLANDA WENDY M , HUGHES PATRICK M , RUIZ GUADALUPE , ORILLA WERHNER C , WHITCUP SCOTT M , LIN JOAN-EN , WELTY DEVIN F
IPC分类号： A61F2/14 , A61K9/00 , A61K9/10 , A61K9/16 , A61K9/50 , A61K31/557 , A61K31/565 , A61K47/34 , A61K47/48
CPC分类号： A61K31/565 , A61F9/0017 , A61K9/0048 , A61K9/0051 , A61K9/10 , A61K9/1635 , A61K9/1694 , A61K9/5031 , A61K31/498 , A61K31/557 , A61K47/34 , Y10S514/913
摘要： Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 10 days and one year or longer.
摘要翻译：尺寸适于植入眼部或部位的可生物降解植入物以及治疗眼部病症的方法。植入物以治疗有效量提供活性剂在10天至1年或更长时间内的延长释放。

25. 发明申请

WO2008019265A3 OCULAR IMPLANT DELIVERY ASSEMBLIES 审中-公开
标题翻译： OCULAR IMPLANT交付组件
公开(公告)号：WO2008019265A3
公开(公告)日：2008-04-10
申请号：PCT/US2007074930
申请日：2007-08-01
申请人： ALLERGAN INC , TROGDEN JOHN T , LYONS ROBERT T , CHANG JAMES N , ROBINSON MICHAEL R
发明人： TROGDEN JOHN T , LYONS ROBERT T , CHANG JAMES N , ROBINSON MICHAEL R
IPC分类号： A61F9/00
CPC分类号： A61F9/0017 , A61K9/0051
摘要： Ocular implant delivery assemblies (10) are provided which include a cannula (12) having a lumen (14) extending therethrough, a proximal end (16), a proximal end opening (18), a distal end (22), a distal end opening (24), and a lumen extending through the cannula. A removable distal closure element (32) is provided for closing the distal end opening, and a removable proximal closure element (36) is provided for closing the proximal end opening. An ocular implant (40) is located in the lumen. The implant may be sealed in the cannula without the addition of a liquid carrier or it may be contained in a liquid carrier medium in the cannula. The implant may be made up of a number of microparticles having different compositions or different forms. The assembly also includes a sleeve (48) located on the proximal end of the cannula and suitable for coupling the assembly to a syringe containing a pushing gel.
摘要翻译：提供了眼部植入物递送组件（10），其包括具有延伸穿过其中的内腔（14）的插管（12），近端（16），近端开口（18），远端（22），远端开口（24）和延伸穿过套管的内腔。提供可移除的远端闭合元件（32）用于封闭远端开口，并且提供可移除的近端闭合元件（36），用于封闭近端开口。眼部植入物（40）位于内腔中。植入物可以密封在套管中而不加入液体载体，或者其可以包含在插管中的液体载体介质中。植入物可以由具有不同组成或不同形式的许多微粒组成。组件还包括位于套管的近端上的套筒（48），并且适于将组件耦合到包含推压凝胶的注射器。

26. 发明申请

WO2007150018A2 STEROID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED METHODS 审中-公开
标题翻译： STEROID含有持续释放内分泌植入物及相关方法
公开(公告)号：WO2007150018A2
公开(公告)日：2007-12-27
申请号：PCT/US2007/071871
申请日：2007-06-22
申请人： ALLERGAN, INC. , WHITCUP, Scott, M. , ROBINSON, Michael, R.
发明人： WHITCUP, Scott, M. , ROBINSON, Michael, R.
IPC分类号： A61K9/22 , A61K31/58
CPC分类号： A61K9/0051 , A61K31/498 , A61K31/573 , A61K31/58 , A61K47/34
摘要： Biocompatible intraocular implant systems are formulated for discontinuous or intermittent release of therapeutic levels of a therapeutic agent (such as a steroid) to minimize development of side effects associated with continuous or long term use of such agent. The implant system may comprise one or more implant, and preferably, although not necessarily, also contains an auxiliary agent having an activity effective to lessen at least one side effect associated with said therapeutic agent compared to the use of an otherwise identical implant system lacking said auxiliary agent. The implants containing the therapeutic agent and auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the ocular side effects otherwise accompanying the use of such therapeutic agent.
摘要翻译：生物相容性眼内植入物系统被配制用于治疗剂量（例如类固醇）的不连续或间歇释放以最小化与这种药剂的连续或长期使用相关的副作用的发展。植入物系统可以包括一个或多个植入物，并且优选但不一定也包含具有有效减轻与所述治疗剂相关联的至少一种副作用的活性的辅助剂，与使用其它相同的植入物系统相比，缺少所述辅助剂。包含治疗剂和辅助剂的植入物可以放置在眼睛中以治疗一种或多种眼部病症，同时减少否则伴随使用这种治疗剂的眼部副作用。

27. 发明申请

WO2011127064A2 SUSTAINED-RELEASE RESERVOIR IMPLANTS FOR INTRACAMERAL DRUG DELIVERY 审中-公开
标题翻译：持续发布储存药物输送的储存植入物
公开(公告)号：WO2011127064A2
公开(公告)日：2011-10-13
申请号：PCT/US2011031265
申请日：2011-04-05
申请人： ALLERGAN INC , SHI RUWEN , HUGHES PATRICK M , BURKE JAMES A , ROBINSON MICHAEL R , LIU HUI
发明人： SHI RUWEN , HUGHES PATRICK M , BURKE JAMES A , ROBINSON MICHAEL R , LIU HUI
IPC分类号： A61K9/00
CPC分类号： A61K9/0051 , A61K9/0092 , A61K31/382 , A61K31/4025 , A61K31/498 , A61K31/5377 , A61K31/5575 , A61K31/5578
摘要： The present invention provides a sustained release implant for intraocular use to treat elevated intraocular pressure, which implant is configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (IOP), said implant comprising a core of an antihypertensive agent surrounded by a polymer, which limits the rate of passage of the antihypertensive agent from the implant into the eye of said patient and said implant provides a linear rate of release of therapeutically effective amounts of said anti-hypertensive agent into the eye for a period of time of between 14 days and 365 days.
摘要翻译：本发明提供了一种用于眼内用于治疗升高的眼内压的持续释放植入物，该植入物构造成用于向眼内压升高的患者进行房内或前玻璃体内施用，所述植入物包含由聚合物，其限制抗高血压剂从植入物进入所述患者的眼睛的速度，并且所述植入物提供治疗有效量的所述抗高血压剂在眼睛中的线性速率释放时间间隔 14天365天。

28. 发明申请

WO2011109384A2 BIODEGRADABLE POLYMERS FOR LOWERING INTRAOCULAR PRESSURE 审中-公开
标题翻译：用于降低内压的生物可降解聚合物
公开(公告)号：WO2011109384A2
公开(公告)日：2011-09-09
申请号：PCT/US2011026670
申请日：2011-03-01
申请人： ALLERGAN INC , ROBINSON MICHAEL R , LEE SUSAN S , WHITCUP SCOTT M
发明人： ROBINSON MICHAEL R , LEE SUSAN S , WHITCUP SCOTT M
IPC分类号： A61K9/00
CPC分类号： A61K31/765 , A61K9/0051 , A61K31/557
摘要： The present invention provides a method of treating glaucoma, the method comprising the step of placing a polymer in an eye of a patient, which biologically degrades over a period of time to release biodegradants, which are effective to lower the intraocular pressure of the patient, thereby treating glaucoma. Said polymer is preferably selected from the group consisting of polymers of lactic acid, glycolic acid and/or mixtures thereof. More preferably the polymer is a copolymer of lactic acid and glycolic acid, e.g. a copolymer comprising from 50 to 100 % lactic acid and from 0 to 50% glycolic acid, by weight.
摘要翻译：本发明提供了一种治疗青光眼的方法，所述方法包括将聚合物置于患者的眼睛中的步骤，所述聚合物在一段时间内生物降解以释放生物降解剂，其有效降低患者的眼内压，从而治疗青光眼。所述聚合物优选选自乳酸，乙醇酸和/或其混合物的聚合物。更优选地，聚合物是乳酸和乙醇酸的共聚物，例如，包含50-100％乳酸和0-50％乙醇酸的共聚物，按重量计。

29. 发明申请

WO2011091205A2 INTRACAMERAL SUSTAINED RELEASE THERAPEUTIC AGENT IMPLANTS 审中-公开
标题翻译：内镜持续释放治疗代理植入物
公开(公告)号：WO2011091205A2
公开(公告)日：2011-07-28
申请号：PCT/US2011/021971
申请日：2011-01-21
申请人： ALLERGAN, INC. , ROBINSON, Michael R. , BURKE, James , SCHIFFMAN, Rhett
发明人： ROBINSON, Michael R. , BURKE, James , SCHIFFMAN, Rhett
IPC分类号： A61K9/00
CPC分类号： A61K9/0051 , A61K9/0024 , A61K9/1647 , A61K31/5575 , A61K47/10 , A61K47/34 , A61L27/18 , A61L27/54 , A61L27/58
摘要： Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.
摘要翻译：本文描述的是包括用于治疗至少一种眼部病症的至少一种治疗剂的植入物植入物。本文所述的植入物不固定在眼组织上，而是通过存在于眼前房中的电流和重力保持在适当位置。植入物优选是聚合的，可生物降解的并且提供至少一种治疗剂持续释放到小梁网和相关联的眼组织和眼睛前房内的流体。

30. 发明申请

WO2010009034A3 METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION 审中-公开
标题翻译：治疗萎缩性年龄相关性黄斑变性的方法
公开(公告)号：WO2010009034A3
公开(公告)日：2010-05-06
申请号：PCT/US2009050373
申请日：2009-07-13
申请人： ALLERGAN INC , ROBINSON MICHAEL R , BLANDA WENDY M , HUGHES PATRICK M , BURKE JAMES A , WHITCUP SCOTT M
发明人： ROBINSON MICHAEL R , BLANDA WENDY M , HUGHES PATRICK M , BURKE JAMES A , WHITCUP SCOTT M
IPC分类号： A61K47/34 , A61K47/36 , A61K47/38 , A61P27/02
CPC分类号： A61K9/0048 , A61K9/0051 , A61K9/1635 , A61K9/1647 , A61K9/1652 , A61K31/712 , A61K47/36 , A61K2039/505 , C07K16/22
摘要： Compositions and methods for treating dry age related macular degeneration (dry AMD) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).
摘要翻译：通过向液体或固体聚合物载体（或两者）中的抗新生血管剂（例如贝伐单抗）的眼内部位施用来治疗与干燥年龄有关的黄斑变性（干性AMD）的组合物和方法，例如生物可降解透明质酸或PLGA（或PLA）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式